Peplin?s lead cancer drug shows positive results against AML
Posted by rob on July 29, 2004 under Uncategorized | 
Be the First to Comment
Peplin Biotech Limited (PEP) today announced that its lead leukaemia molecule had shown highly selective activity against acute myelogenous leukaemia (AML) in pre-clinical studies. Peplin said that based on the results and other pre-clinical data it intended to prepare and lodge an IND application with the US FDA, to initiate clinical trials of an intravenous formulation of the drug to treat leukaemia.
Add A Comment
You must be logged in to post a comment.